Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Akebia Therapeutics (AKBA) Accumulated Depreciation & Amortization (2016 - 2022)

Akebia Therapeutics (AKBA) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $1.7 million as the latest value for Q4 2022.

  • Quarterly Accumulated Depreciation & Amortization fell 14.17% to $1.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2022, down 14.17% year-over-year, with the annual reading at $1.7 million for FY2022, 14.17% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2022 was $1.7 million at Akebia Therapeutics, down from $1.9 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $5.2 million in Q3 2020, with the low at $899000.0 in Q4 2018.
  • Average Accumulated Depreciation & Amortization over 5 years is $2.6 million, with a median of $2.2 million recorded in 2019.
  • The sharpest move saw Accumulated Depreciation & Amortization decreased 15.11% in 2018, then skyrocketed 149.72% in 2019.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $899000.0 in 2018, then surged by 149.72% to $2.2 million in 2019, then decreased by 7.57% to $2.1 million in 2020, then decreased by 7.13% to $1.9 million in 2021, then decreased by 14.17% to $1.7 million in 2022.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $1.7 million, $1.9 million, and $2.1 million for Q4 2022, Q4 2021, and Q4 2020 respectively.